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ABSTRACT
Background: Immunodeficiency, centromeric instability
and facial dysmorphism (ICF syndrome) is a rare
autosomal recessive disease characterised by facial
dysmorphism, immunoglobulin deficiency and branching
of chromosomes 1, 9 and 16 after PHA stimulation of
lymphocytes. Hypomethylation of DNA of a small fraction
of the genome is an unusual feature of ICF patients which
is explained by mutations in the DNA methyltransferase
gene DNMT3B in some, but not all, ICF patients.
Objective: To obtain a comprehensive description of the
clinical features of this syndrome as well as genotype–
phenotype correlations in ICF patients.
Methods: Data on ICF patients were obtained by
literature search and additional information by means of
questionnaires to corresponding authors.
Results and conclusions: 45 patients all with proven
centromeric instability were included in this study. Facial
dysmorphism was found to be a common characteristic
(n = 41/42), especially epicanthic folds, hypertelorism,
flat nasal bridge and low set ears. Hypo- or agamma-
globulinaemia was demonstrated in nearly all patients
(n = 39/44). Opportunistic infections were seen in several
patients, pointing to a T cell dysfunction. Haematological
malignancy was documented in two patients. Life
expectancy of ICF patients is poor, especially those with
severe infections in infancy or chronic gastrointestinal
problems and failure to thrive. Early diagnosis of ICF is
important since early introduction of immunoglobulin
supplementation can improve the course of the disease.
Allogeneic stem cell transplantation should be considered
as a therapeutic option in patients with severe infections
or failure to thrive. Only 19 of 34 patients showed
mutations in DNMT3B, suggesting genetic heterogeneity.
No genotype–phenotype correlation was found between
patients with and without DNMT3B mutations.
In 1978 two patients were reported independently
who shared specific facial characteristics, immuno-
deficiency and instability of pericentromeric
regions of chromosomes 1, 9 and 16 upon
cytogenetic testing (ICF syndrome).1 2 So far some
30 patients have been reported,3–28 most of them at
very young age. In most patients reduced serum
immunoglobulin levels as well as severe recurrent,
and often fatal, infections were documented. Mild
facial anomalies are a common characteristic of
which epicanthic folds, hypertelorism and a flat
nasal bridge are most frequently reported.
Centromeric instability is the hallmark of the
disease with ICF patients. In only a small
percentage of the genome, most notably on the
sat 2 and 3 repeats on chromosome 1, 9 and 16,
DNA methylation is strongly reduced.29 30
Decondensation of these regions leads to the
characteristic cytogenetic abnormalities which are
prone to breakage and rejoining, leading to the
formation of multiradiate chromosomes in mito-
gen-stimulated lymphocytes.15 In 1998 a locus
associated with ICF syndrome was mapped to
the proximal long arm of chromosome 20.31 This
region contains a de novo DNA methyltransferase
gene, DNMT3B, and mutations in this gene were
identified in ICF patients.32 33 However, mutations
were not demonstrated in all patients investigated,
suggesting involvement of other genes in ICF
syndrome.34
The aim of the present study was to obtain a
comprehensive description of the clinical features
of ICF syndrome, the natural history as well as
possible genotype–phenotype correlations in such
patients.
PATIENTS AND METHODS
A computer assisted literature search using
Pubmed and EMBASE was conducted to identify
and obtain data on patients with ICF syndrome.
Only patients showing the cytogenetic hallmark of
the diagnosis—that is, instability of the pericen-
tromeric heterochromatin of chromosomes 1, 9 and
16 upon PHA stimulation—were included in the
study. Supplementary information was obtained
from questionnaires completed by their attending
physicians. Data of patients previously reported in
the literature (n = 32) were updated and new
patients (n = 13) have been included. Ethical
approval was obtained for the publication of these
data.
Questions focused on age at diagnosis, facial
anomalies, psychomotor development, hypotonia
and gastrointestinal problems. The diagnosis of
immunodeficiency was made by reductions of
serum IgG, IgG subclasses, IgA and/or IgM
according to age standardised reference ranges.
Agammaglobulinaemia was defined as a decrease of
IgG below 2.5 g/l. Special attention was given to
frequency and type of infections and laboratory
results reflecting immunological status. These
included complete blood count, level of serum
immunoglobulins G, A, M, E and IgG subclasses
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and number of T and B lymphocyte subpopulations.
RESULTS
A total of 45 ICF patients were included in this study (table 1).
Sociodemographic features
The 45 patients include 25 males and 20 females, originating
from 39 families, with consanguinity confirmed in 18 patients
(table 1). There were six sibling pairs. In two children with a
positive family history the diagnosis of ICF was confirmed
shortly after birth through genetic analysis on cord blood
(patient 16, 33).
Seventeen patients (40.5%) died, with cause of death being
predominantly severe respiratory tract infections, sepsis and
failure to thrive. Median age at death was 8 years (range
6 months–42 years).
Facial anomalies
In most evaluable patients (41/42) typical distinctive facial
appearances were found (fig 1, table 2). Hypertelorism, flat
nasal bridge, epicanthic folds and low set ears were most
frequent. The combination of epicanthic folds, hypertelorism,
flat nasal bridge and low set ears was observed in 11 cases.
Among those patients who were followed into adulthood only
one had no facial anomalies (patient 25). Patient 30 had
complaints of chronic fatigue at the age of 17, due to a sleep/
apnoea syndrome caused by anatomic anomalies of the tongue.
Congenital defects
The most common malformations found were inguinal hernia
and hypospadia (4/42), cleft palate (3/42) and syndactyly (2/
42). Cardiac anomalies were reported in two patients and
included a ventricular septal defect and an atrial septal defect
(patients 31 and 39, respectively). Congenital hypothyroidism
was found in one patient (patient 42).
Cerebral malformations were reported in individual patients
and include focal cortical heterotopy, corpus callosum hypopla-
sia and hydrocephalus (patients 40, 8 and 5, respectively).
Immunodeficiency and infections
With the exception of one (patient 14), all remaining patients
had documented signs of immunodeficiency (table 1). Patient 5
died at 6 months; follow up was too short in order to draw
conclusions regarding the immune status. In 27 patients the
immunoglobulin levels were consistent with a diagnosis
agammaglobulinaemia; they all had B cells. Twelve patients
had decreased levels of all immunoglobulins and four patients
were reported with selective IgA (patient 2), IgM (patients 13
and 21) and IgG2 subclass deficiency (patient 19). The diagnosis
of hypo/agammaglobulinaemia was made in early childhood in
all patients (median age 3 years). Data for T cell subpopulations
were available for 38 patients (table 2). Normal percentages of T
cells were observed in all but two patients (patients 5 and 9),
and CD4 positive cells were decreased (,p10) in five of 38
patients (13.1%). A limited number of patients underwent T cell
function testing in vitro. Of the 28 tested, three patients
showed decreased or absent proliferation when stimulated with
the mitogen PHA.
At the time of data collection, 29 patients were receiving
intravenous immunoglobulin (IVIG) replacement.
Infections were a prominent clinical feature for 43 patients
with available data (table 2) and were the leading cause of death
(table 1) for 12 patients (26.6%). The most common were
respiratory tract infections in 35 patients (81.4%). Three
patients were reported with Pneumocystis jiroveci pneumonia
(patients 11, 29 and 43). Sepsis was reported in 10 patients. In
six patients, positive blood cultures were reported including
Staphylococcus aureus (patients 3 and 13), Pseudomonas (patients
17 and 45) and Klebsiella species (patients 15 and 29).
Streptococcus pneumoniae meningitis was documented in one
patient (patient 39) and persistent Candida stomatitis in six
(patients 5, 8, 9, 10, 44 and 45). Patient 13, with known selective
IgM deficiency, developed a progressive multifocal leucoence-
phalopathy, due to JC virus14 at the age of 35 years; at that
moment she had an agammaglobulinaemia. Infections with JC
virus, Pneumocystis jiroveci and Candida suggest that a subtle
defect of T cell function must be present, apart from the
hypogammaglobulinaemia.
Gastrointestinal problems were reported in 27 patients
(65.8%) (table 2) and included multiple episodes of acute
diarrhoea in 18 patients (43.9%). Seven had chronic diarrhoea,
two with persistent bacterial enteritis (salmonella in patient 6;
campylobacter in patient 33). For three patients (patients 8, 15
and 29) diarrhoea was severe enough to warrant the adminis-
tration of total parenteral nutrition for several months.
In four patients allogeneic stem cell transplantation (alloSCT)
has been performed (patient 24 because of MDS; patients 33, 34
and 43 for infections and failure to thrive).
Malignancies and haematological abnormalities
Haematological malignancies were reported in two patients and
included one patient who developed a classical Hodgkin
lymphoma (patient 37),25 and a second patient who developed
myelodysplastic syndrome (patient 24). Patient 45 developed
aplastic anaemia. An adrenocortical adenoma was described in
one patient (patient 39). Acquired leucopenia and thrombocy-
topenia of unknown origin were documented in patients 16, 30
and 41. In two of them (patients 16 and 41) cortical atrophy
evolved at the same time without evidence of an infectious
origin.
Growth, development and neurological problems
The average gestational age was 38 weeks (range 30–42 weeks).
Eight patients (18.6%) were born preterm. Among the 35
patients with adequate growth records, 20 (57.1%) had a birth
weight below the 10th centile (table 2) according to the World
Health Organization Child Growth Standard. Data regarding
sexual maturation were available in 10 cases: all entered puberty
normally.
Developmental milestones were delayed in 28 of 41 patients
(68.3%). Of these, 18 (43.9%) were delayed in speech develop-
ment and 21 (51.2%) did not start walking until 18 months of
age. Nine patients with a delayed motor development were
reported with hypotonia. Intelligence quotients were available
from 44 patients, with 17 (38.6%) showing a normal intelli-
gence, 17 (38.6%) a mild retardation and 10 (22.7%) moderate
retardation.
Five patients (patients 2, 12, 16, 18 and 41) had cortical
atrophy. Two of them (patients 12 and 18) developed general-
ised tonic–clonic seizures within their first 2 years of life. Two
other patients (patients 2 and 16) had a progressive deteriora-
tion of cognitive functions at the age of 10 years.
Genetics
A total of 35 individuals with the syndrome were screened for
mutations of the gene DNMT3B (table 1). Mutations were
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detected in 20 (57.1%) cases. Ten patients showed a homo-
zygous mutation, the remainder were compound heterozygous.
The homozygous patients were all of proven consanguineous
descent. One patient (patient 25) born from non-consangui-
neous parents had a single mutation. The majority of mutations
are missense mutations (table 1). Other mutations included
nonsense mutations and splice-site mutations.
In order to study a possible genotype–phenotype correlation the
cases in this report were divided into two groups based on
mutation data. Group 1 entailed those with DNMT3B mutation
(n = 20), and group 2 included those without mutation after DNA
analysis (n = 15). As shown in table 2, no relevant differences were
noted concerning immunology, facial findings and development.
The number and severity of infections was similar in both groups.
DISCUSSION
The diagnosis of ICF is based on the triad of immunodeficiency,
centromeric region instability and facial dysmorphism.1 2 The
clinical spectrum in this study group, however, was very broad.
In this study of cytogenetically proven ICF patients it became
clear that these hallmarks are not equally present in all patients.
While centromeric region instability was by definition present
in all patients, facial dysmorphism was lacking in some and the
immune defect varied from a severe combined immunodefi-
ciency to nearly normal immunity.
In most patients facial dysmorphism was present and
included hypertelorism, flat nasal bridge, epicanthic folds, low
set ears, micrognathia or upturned nose. One patient developed
a nocturnal sleep apnoea syndrome due to abnormalities of the
tongue and motor problems of the mouth (patient 30). Obvious
facial dysmorphism at birth without other symptoms at that
time was the reason for cytogenetic studies in one patient
(patient 42), leading to the diagnosis of ICF syndrome. Another
patient (patient 25) did not have dysmorphism at all, while
Figure 1 Patient with typical ICF features: hypertelorism, epicanthic
folds, flat nasal bridge and up turned nose. Parental/guardian informed
consent was obtained for publication of this figure.
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patient 16 had normal features at birth and developed
dysmorphism during childhood. Therefore, absent dysmorph-
ism in patients with agammaglobulinaemia, in whom B cells are
present, does not preclude ICF syndrome and cytogenetic
analysis should be considered. In addition a variety of congenital
malformations were seen suggesting that DNMT3B plays an
important broad role during embryogenesis. Further evidence
for the role of DNMT3B in embryogenesis/morphogenesis was
recently provided in transgenic mice models.35
The most prominent clinical feature in the study group was
respiratory tract infections, with at least one episode of
bronchopneumonia occurring in nearly all of the cases. Severe
pulmonary infections were also the most common cause of
death, indicative of the severity of immunodeficiency in these
patients. By an unknown mechanism it is possible that
DNMT3B mutations—probably as a result of DNA hypomethy-
lation—are involved in lymphogenesis dysregulation causing
this immunodeficiency.36
Two patients with a positive family history of ICF were
treated from birth with IVIG and did not have pulmonary
infections in infancy. This has also been described in patients
with X-linked agammaglobulinaemia (XLA), who are now
surviving into adulthood with fewer pulmonary problems due
to earlier treatment with IVIG.37
Normally, infections in patients with agammaglobulinaemia are
mostly caused by pyogenic encapsulated bacteria such as
Streptococcus pneumoniae or Haemophilus influenzae. These micro-
organisms were observed in only a minority of the ICF patients.
Opportunistic infections such as Pneumocystis jiroveci or severe
candida stomatitis occurred in several ICF patients with appar-
ently only a B cell defect and normal T cell numbers and function.
This suggests that a subtle defect of T cell function or a defect
in antigen presenting cells (dendritic cells or monocytes) must
be present. Studies in murine ICF models have demonstrated an
effect on postnatal thymocyte survival.35 Further studies are
required to determine the impact on peripheral T cell popula-
tions and their function in these mice and ICF patients. In
practical terms this means that prophylaxis with co-trimoxazole
should be employed.
A high proportion of the children died at a young age from
respiratory infections or failure to thrive. In particular, children
with gastrointestinal problems in combination with failure to
thrive had a poor prognosis, leading to a worsening of the
disease. Because the prognosis is poor in the patients with severe
infections or failure to thrive, alloSCT should be considered in
those patients. Recent experience indicates that alloSCT can be
safely performed in ICF patients with improvement in immune
function and clinical outcome.38
This study shows that growth retardation is a frequent
problem in ICF patients. It is possible that initial growth
problems were related to low birth weight. Furthermore, a
number of children (43.9%) suffered diarrhoea secondary to
infections or other gastrointestinal problems, and half the
children failed to thrive (51.2%). In the case of two brothers
with ICF, the elder with intestinal problems had poor growth,
but his younger brother who was treated from birth with
immunoglobulin substitution did not suffer from chronic
diarrhoea, and had normal growth. This suggests that the poor
growth is not directly related to the genetic defect.
One of the first reported patients with ICF suffered from
severe mental retardation.2 We here demonstrate that, although
the majority of children with ICF syndrome do have some
degree of mental retardation (27/44, 61%), more than one third
(16/41, 39%) have normal intelligence. One child was reported
as doing exceptionally well in high school showing that the
disorder can exist without retardation. Children with ICF in
this cohort frequently have difficulty with speech and gross
motor skills. Physiotherapeutic support and speech therapy
often has positive influence on their development. Neurological
problems may develop over time. In three ICF patients (patients
2, 16 and 41) non-infectious encephalopathy was seen.
Progressive deterioration and/or thrombocytopenia and leuco-
penia in combination with cerebral atrophy is similar to the
pathology of neurological manifestations in systemic lupus
erythematosus which is linked to DNA hypomethylation.39
Development of haematological abnormalities—for example,
aplastic anaemia in patient 45, or thrombocytopenia and
Table 2 Clinical data and results of immunological analyses in relation
to presence or absence of DNMT3B mutation
Total*
DNMT3B
mutation No mutation
Demographic features Total 45 Total 20{ Total 15{
Consanguine 18/45 10/20 4/15
Died 17/42 5/18 3/15
Growth and development
Gestational age ,37 weeks 8/43 2/18 4/15
Birth weight (p10 20/35 6/17 6/8
Failure to thrive 21/41 6/16 8/15
Delays in motor development 21/41 10/17 9/15
Delays in speech and language development 18/41 7/14 7/15
Intelligence
Normal intelligence 17/44 11/20 4/15
Mild retardation 17/44 4/20 8/15
Moderate retardation 10/44 5/20 3/15
Craniofacial features
Hypertelorism 27/42 10/18 10/15
Flat nasal bridge 25/42 13/18 9/15
Epicanthus 25/42 13/18 7/15
Low set ears 20/42 8/18 7/15
Micrognathia 12/42 5/18 4/15
Up-turned nose 14/42 6/18 6/15
Round face 11/42 7/18 3/15
Macroglossia 8/42 4/18 3/15
Telecanthus 9/42 4/18 2/15
High forehead 10/42 3/18 3/15
Tongue protrusion 7/42 2/18 3/15
Congenital malformation 17/42 3/18 4/15
Gastrointestinal problems
Diarrhoea 18/41 7/16 6/15
Malabsorption 4/41 2/16 1/15
Infections
Bronchopneumonia 35/43 15/18 11/15
Otitis 13/43 8/18 3/15
Sepsis 8/43 2/18 6/15
Candida infection 6/33 2/18 0/15
Pneumocystis jerovici 3/33 2/18 1/15
Neurology
Cerebral atrophy 5/45 2/20 2/15
Seizures 3/45 0/20 2/15
Immunology
Agammaglobulinaemia 26/45 14/20 8/15
Hypogammaglobulinaemia 12/45 5/20 4/15
IgM deficiency 2/45 0/20 1/15
IgA deficiency 1/45 1/20 0/15
IgG2 subclass deficiency 1/45 0/20 0/15
T cells
CD 4 decreased 7/38 2/17 2/15
*All cytogenetically proven ICF patients.
{10 patients who were not screened for DNMT3B mutation are not listed.
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leucocytopenia seen in patient 30, who also developed
hepatosplenomegaly and gonarthritis—may be caused by
autoimmune mechanisms. Autoimmunity in the absence of
antibodies suggests activation of autoreactive T cells by T cell
receptor or innate activating receptors directly.
A predisposition to cancer is frequently associated with
immunodeficiency. Various types of cancer such as breast
adenocarcinomas,40 ovarian epithelial carcinomas41 and Wilms
tumours42 share with ICF syndrome cells the characteristic of
hypomethylated satellite 2 DNA. It has been proposed that
hypomethylation of this area affects chromatin structure leading
to chromosomal instability as well as possibly altered gene
expression.43 It is unclear whether the malignancy seen in patients
24 and 37 was a chance association or linked to the ICF syndrome.
Only 20 of the 35 patients tested showed mutations in
DNMT3B, suggesting genetic heterogeneity. No genotype–
phenotype correlation was found. Thus patients with muta-
tions in the DNMT3B gene have the same phenotype as patients
without this mutation (table 2). In those with a demonstrable
mutation, the phenotype differed widely. Two factors influ-
enced our ability to demonstrate a genotype–phenotype
correlation in this study: (1) the number of proven ICF patients
was small; and (2) most patients were compound heterozygotes
and most mutations occurred only once.34 It is likely that a
complex interaction of factors leads to the broad variation in
phenotypic characteristics as seen in ICF syndrome.
In conclusion, ICF syndrome should be considered in all
patients with agammaglobulinaemia with B cells or common
variable immunodeficiency, where other features such as a
history of delayed milestones raise the possibility of ICF. Early
diagnosis is important since early treatment with IVIG can
improve the natural history of the disease. AlloSCT should be
considered as a therapeutic option in patients with severe
infections or failure to thrive.
This review of the spectrum of ICF features should contribute
to a better recognition of ICF patients. Close follow up and
central registration of patients will allow the prevalence and the
natural history of the syndrome to become clearer.
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